Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Details) - Schedule of stock options outstanding and exercisable

v3.21.2
Stockholders' Equity (Details) - Schedule of stock options outstanding and exercisable
 9 Months Ended
Sep. 30, 2021
$ / shares
shares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Stock Options, Weighted Average Exercise Price
Stock Options, Total Outstanding (in Shares) (in Shares) | shares 11,164,621
Stock Options, Number Exercisable (in Shares) (in Shares) | shares 6,064,329
Grant Price From 0.26 to 2.02 [Member]  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Stock Options, Grant Price, Minimum $ 0.26
Stock Options, Weighted Average Exercise Price $ 1.15
Stock Options, Total Outstanding (in Shares) (in Shares) | shares 7,670,746
Stock Options, Number Exercisable (in Shares) (in Shares) | shares 2,608,226
Stock Options, Weighted Average Remaining Contractual Term 7 years 8 months 1 day
Stock Options, Grant Price, Maximum $ 2.02
Grant Price From 2.10 to 4.60 [Member]  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Stock Options, Grant Price, Minimum 2.1
Stock Options, Weighted Average Exercise Price $ 2.47
Stock Options, Total Outstanding (in Shares) (in Shares) | shares 2,900,875
Stock Options, Number Exercisable (in Shares) (in Shares) | shares 2,884,582
Stock Options, Weighted Average Remaining Contractual Term 7 years 11 months 1 day
Stock Options, Grant Price, Maximum $ 4.6
Grant Price From 5.30 to 8.86 [Member]  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Stock Options, Grant Price, Minimum 5.3
Stock Options, Weighted Average Exercise Price $ 6.25
Stock Options, Total Outstanding (in Shares) (in Shares) | shares 593,000
Stock Options, Number Exercisable (in Shares) (in Shares) | shares 571,521
Stock Options, Weighted Average Remaining Contractual Term 6 years 7 months 2 days
Stock Options, Grant Price, Maximum $ 8.86